SRR33346956
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.520
- ALLOGRAFT_REJECTION+0.480
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.390
- HEDGEHOG_SIGNALING+0.380
- INTERFERON_GAMMA_RESPONSE+0.340
- COMPLEMENT+0.320
- COAGULATION+0.270
- ANGIOGENESIS+0.260
- IL2_STAT5_SIGNALING+0.220
Top 10 suppressed
- MYC_TARGETS_V1-0.620
- OXIDATIVE_PHOSPHORYLATION-0.580
- MYC_TARGETS_V2-0.520
- FATTY_ACID_METABOLISM-0.430
- MTORC1_SIGNALING-0.430
- PROTEIN_SECRETION-0.430
- ADIPOGENESIS-0.420
- CHOLESTEROL_HOMEOSTASIS-0.420
- E2F_TARGETS-0.410
- PEROXISOME-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AQ-A7U7-01A-22R-A352-07 | — | D | 0.913 |
| 2 | X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e | — | cohortMD2 | 0.911 |
| 3 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.909 |
| 4 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.906 |
| 5 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.905 |
| 6 | DRR168543 | — | — | 0.902 |
| 7 | SRR12202445 | — | — | 0.901 |
| 8 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.895 |
| 9 | TCGA-49-AARO-01A-12R-A41B-07 | — | cohortA1 | 0.894 |
| 10 | SRR6013478 | — | cohortMD2 | 0.892 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.340 | Idelalisib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.110 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.090 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |